source
- Sanofi drops pursuit of eczema drug amlitelimab after failed Phase 3 trialsSanofi announced it will no longer seek regulatory approval for amlitelimab, an anti‑OX40 ligand antibody intended for atopic dermatitis, after recent Phase 3 data fell short of expectations. The…
- FDA issues early alert on Boston Scientific ENROUTE catheter tip separation riskThe CDRH has issued an Early Alert warning about a potential high risk issue with Boston Scientific's ENROUTE Transcarotid Neuroprotection System and its Plus version. The problem involves possibl…